Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy

Bone Marrow Transplantation

Volumn 47, Issue 9, 2012, Pages 1217-1221

  Ljungman, P ^a   Locasciulli, A ^b   De Soria, V G ^c   Bekassy A N ^d   Brinch, L ^e   Espigado, I ^f   Ferrant, A ^g   Franklin, I M ^h   O'Riordan, J ⁱ   Rovira, M ^j   Shaw, P ^k   Einsele, H ^l  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ ST JAMES S HOSPITAL   (Ireland)

^j HOSPITAL CLÍNIC   (Spain)

^k CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^l UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

antiviral therapy; Hepatitis C virus; late effects

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; INFANT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865966560     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.238     Document Type: Article

References (19)

1. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893-1899. (Pubitemid 29247066)
2. Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93: 3259-3266. (Pubitemid 29220892)
3. Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L et al. Longterm outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-1624. (Pubitemid 38268950)
4. Ivantes CA, Amarante H, Ioshii SO, Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004; 33: 1181-1185. (Pubitemid 38961474)
5. Ljungman P, Andersson J, Aschan J, Bjö rkstrand B, Hägglund H, Lö nnqvist B et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996; 23: 167-169. (Pubitemid 26323813)
6. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004.
7. Locasciulli A, Testa M, Valsecchi MG, Bacigalupo A, Solinas S, Tomas JF et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999; 68: 1486-1491.
8. Ljungman P, Johansson N, Aschan J, Glaumann H, Lö nnqvist B, Ringd:en O et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995; 86: 1614-1618.
9. Locasciulli A, Bacigalupo A, VanLint MT, Cavalletto D, Pontisso P, Testa M et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 407-411.
10. Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249-257.
11. Sinn DH, Paik SW, Kang P, Kil JS, Park SU, Lee SY et al. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008; 28: 1363-1369.
12. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42: 513-521. (Pubitemid 47190067)
13. Peffault de Latour R, Asselah T, Levy V, Scieux C, Devergie A, Ribaud P et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005; 36: 709-713. (Pubitemid 41518714)
14. Kayali Z, Tan S, Shinkunas L, Voigt M, LaBrecque DR, Stapleton JT et al. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat 2007; 14: 11-21. (Pubitemid 46012356)
15. Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006; 7: 331-337. (Pubitemid 43805694)
16. Thursz M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut 2007; 56: 613-614. (Pubitemid 46662924)
17. Fuiano B, Pannullo A, Annovazzi G, D0Anna C, Materazzetti D, Nestola G et al. Risk factors and association with HBV infection in chronic C hepatitis. Ital J Gastroenterol 1992; 24: 409-411.
18. Zimmermann T, Otto C, Hoppe-Lotichius M, Biesterfeld S, Lautem A, Knaak M et al. Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation. Transplant Proc 2009; 41: 2549-2556.
19. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 2009; 81: 2029-2035.